MiMedx Group (MDXG)

• Market cap: $1.03B
• 1 day: 0.43%
• 5 days: -2.79%
• 1 month: -1.97%
• 3 months: 16.36%
• 6 months: -13.31%
• Year to date: -24.89%
• 1 year: 12.06%
• 5 years: -3.6%
• 10 years: -32.59%
• Sector: Healthcare
• Industry: Biotechnology

About: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Employees: 837

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

25% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 24

14% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 65

2% more funds holding

Funds holding: 217 [Q1] → 222 (+5) [Q2]

1.51% more ownership

Funds ownership: 69.0% [Q1] → 70.51% (+1.51%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

18% less capital invested

Capital invested by funds: $773M [Q1] → $636M (-$136M) [Q2]

46% less call options, than puts

Call options by funds: $353K | Put options by funds: $650K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12
• Avg. target: $12
• High target: $12

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Ross Osborn

$12

Overweight Maintained

31 Jul 2025